Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Non-Current Liabilities (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $46.5 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 0.6% to $46.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.5 million through Dec 2025, down 0.6% year-over-year, with the annual reading at $46.5 million for FY2025, 0.6% down from the prior year.
  • Total Non-Current Liabilities hit $46.5 million in Q4 2025 for Cumberland Pharmaceuticals, up from $34.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $49.4 million in Q4 2022 to a low of $33.2 million in Q2 2021.
  • Historically, Total Non-Current Liabilities has averaged $42.0 million across 5 years, with a median of $45.1 million in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 43.64% in 2022 and later dropped 26.16% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $34.4 million in 2021, then soared by 43.64% to $49.4 million in 2022, then fell by 6.69% to $46.1 million in 2023, then rose by 1.47% to $46.7 million in 2024, then dropped by 0.6% to $46.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CPIX at $46.5 million in Q4 2025, $34.1 million in Q3 2025, and $33.9 million in Q2 2025.